College students' insomnia linked more strongly to loneliness than screen time

Published Date: 11 Dec 2024

Being lonely is a bigger hurdle to a good night's sleep for college students than too much time at a computer or other electronic screen, a new study by Oregon State University suggests.

Read Full News

Latest News

8 Pulmonology Headlines You Missed in September 2026

8 Pulmonology Headlines You Missed in September 2026

Dupilumab Outperforms Omalizumab for Asthma Remission in Phase 4 EVEREST Guy Brusselle, MD, PhD

Guy Brusselle, MD, PhD, says that 64% of dupilumab-treated patients met composite asthma clinical remission criteria at week 24 versus 40.5% with omalizumab.

What 2 Seasons of Arexvy Data Reveal About RSV-Related Risk Reduction Ann Falsey, MD

Two-season real-world data show Arexvy reduces RSV-related MACE and COPD and asthma exacerbations in adults 60 and older, Ann Falsey, MD, says.

Insurance Formularies Holding Up Lower-Emission Asthma, COPD Inhalers

— Options that reduce greenhouse gases face lower rates of coverage and more administrative hurdles

Pulmonary NPs Debate Biologic Escalation in Asthma, COPD Care Victoria Johnson

Nurse practitioners discuss escalating biologic therapy for asthma and COPD, mucus plugging data, and access barriers.

Why Doctors Need to Complete the COPD or Asthma Workup to Rule Out Alpha-1 Kyle Hogarth, MD

Kyle Hogarth, MD, urges physicians to complete Alpha-1 testing during every COPD or asthma workup, warning that skipped tests delay diagnosis.

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Latest News

8 Pulmonology Headlines You Missed in September 2026

Guy Brusselle, MD, PhD, says that 64% of dupilumab-treated patients met composite asthma clinical remission criteria at week 24 versus 40.5% with omalizumab.

Two-season real-world data show Arexvy reduces RSV-related MACE and COPD and asthma exacerbations in adults 60 and older, Ann Falsey, MD, says.

— Options that reduce greenhouse gases face lower rates of coverage and more administrative hurdles

Nurse practitioners discuss escalating biologic therapy for asthma and COPD, mucus plugging data, and access barriers.

Kyle Hogarth, MD, urges physicians to complete Alpha-1 testing during every COPD or asthma workup, warning that skipped tests delay diagnosis.

News All Time

STAT6 Degraders: Accessible Biologic-Like Asthma Care? With Njira Lugogo, MD Njira Lugogo, MD

Lugogo, ofUniversity of Michigan, discusses how oral STAT6 degraders like KT-621 could expand biologic-like asthma treatment beyond highest severity.

Semaglutide Cuts Asthma Attacks by up to 40% in Real-World Study Victoria Johnson

Semaglutide was linked to fewer asthma attacks and COPD flare-ups than sulfonylureas, with no effect seen for other GLP-1 therapies.

Tozorakimab Cuts COPD Exacerbations Across Eosinophil Levels: Frank Sciurba, MD Frank C. Sciurba, MD

Sciurba, of University of Pittsburgh, discusses full phase 3 OBERON and TITANIA results, including stronger responses in current smokers.

Verekitug's TSLP Mechanism and VALIANT Trial Results, With Michael Wechsler, MD Michael Wechsler, MD, MSc

Wechsler walks through verekitug's mechanism, VALIANT's design, key efficacy and safety findings, and what's next for TSLP-targeted asthma therapy.

AIRCULES: Lunsekimig Benefit Scales With Severity, With Njira Lugogo, MD Njira Lugogo, MD

Phase 2b subgroup data showed lunsekimig's exacerbation benefit scaled with asthma severity and biomarker levels.

Oral STAT6 Degraders Fill Niche in Asthma Care, With Michael Wechsler, MD Michael Wechsler, MD, MSc

Wechsler, of National Jewish Health discusses how oral STAT6 degraders like KT-621 could offer a mechanistically distinct treatment option.

Rademikibart Improves FEV1 in Phase 2 Asthma Exacerbation Trial Victoria Johnson

However, Connect Biopharma's phase 2 Seabreeze STAT Asthma trial's primary treatment-failure end point missed statistical significance.

FIBRONEER-ON: Nerandomilast's Durable IPF, PPF Safety, With Wim Wuyts, MD, PhD Wim Wuyts, MD, PhD

Wuyts, of University Hospitals Leuven discusses interim FIBRONEER-ON open-label extension data showing nerandomilast's favorable safety profile.

Dupilumab Cuts COPD Exacerbations Across Seasons, Smoking Status: Surya Bhatt, MD Surya P. Bhatt, MD

Bhatt also discusses how these findings inform the choice between dupilumab and mepolizumab under GOLD 2026.

STAT6 Degradation: A Novel Oral Target for Asthma? Victoria Johnson

At ERS 2026, pulmonologists framed oral STAT6 degradation—led by Kymera's KT-621—as a potential biologic-like, access-expanding approach.

ERS Congress 2026: 6 Late-Breaking Trials to Know Victoria Johnson

Read 6 late-breaking updates from ERS Congress 2026 that clinicians managing respiratory disease should know.

FDA Grants Priority Review for Insmed's ARIKAYCE sNDA for MAC Lung Disease

FDA Grants Priority Review for Insmed's ARIKAYCE sNDA for MAC Lung Disease

FDA Updates Sotatercept Label with HYPERION Data in Early PAH

FDA Updates Sotatercept Label with HYPERION Data in Early PAH

Using AI for COPD Diagnosis, Equity, Guideline Gaps: Alvar Agusti, MD, PhD

Using AI for COPD Diagnosis, Equity, Guideline Gaps: Alvar Agusti, MD, PhD

PAH Experts Discuss Trial-to-Clinic Mismatch in Care

PAH Experts Discuss Trial-to-Clinic Mismatch in Care

Bridging the ROS1 Divide: Translating Biomarker Insights and Therapeutic Advances Into Community Oncology Practice for NSCLC

Bridging the ROS1 Divide: Translating Biomarker Insights and Therapeutic Advances Into Community Oncology Practice for NSCLC

Recommended News For You

Virtual Reality Travel Reduces Cancer Pain.

For older patients with Hodgkin lymphoma, novel regimens produce high response rates.

Screening for prostate cancer: is it time to give up digital rectal examination?

Hospitalized Kate Middleton; Sen. Paul Demands That Fauci Go To Prison; COVID Returns to Class.

EGFR Inhibitors for Lung Cancer Tied to Increased Keratitis Risk.

For treatment, the majority of cancer patients choose complementary therapies.

Cardiorespiratory fitness lowers the risk of colon, lung, and prostate cancer in MEN and lowers mortality from these diseases.

Recommended Articles For You

Tertiary Lymphoid Structures in Cancer: Advancing Therapeutic Implications 

Genomic Control of Erythropoietic Stem Cell Renewal 

Fatigue, Vitality, and Quality of Life in Hematologic Disorders 

Advancements in Cancer Treatment Strategies for Non-Hodgkin Lymphoma 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Global inequalities found in cancer research funding

2.

Breast cancer surgery: Study finds overnight hospital stay not important for older patients

3.

Pomalidomide Reduces Severe Epistaxis in Hereditary Bleeding Disease.

4.

AI System Beats Radiologists in Detecting Clinically Significant Prostate Cancer

5.

Fighting for others: How guilt and obligation drive desire for more intensive treatments in end-of-life cancer care

1.

Advancing Cancer Trials: Integrating Master Protocols and Immunotherapy Guidelines

2.

Transforming Cancer Care: CAR T-Cell Therapy for Relapsed/Refractory NHL and ALL

3.

AI-Powered Strategies for Precision and Improved Outcomes in Esophageal Cancer, a Global Health Crisis

4.

All About Ferric Gluconate – The Best Source Of Iron For Anemia

5.

Cancer in 2024: Global Trends, Challenges, and Innovations for Healthcare Professionals

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

1.

How Advances in Cancer Research Are Improving Treatment Options

2.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part V

3.

Comprehensive Update on Hematology

4.

Recognizing Symptoms of Vitamin B12 Deficiency

5.

Understanding the causes of anemia in adults beyond nutritional deficiencies

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot